Prescription ID | TCMF654 |
Pinyin Name | Ru He San Jie Pian |
Chinese Name | 乳核散结片 |
English Name | Ru He San Jie Tablet |
Function Description | 乳癖, 乳核 |
Indications | Breast lump disorder |
Disease ICD-11 Category |
SC24 [Breast lump disorder (TM1), 乳癖 (TM1)
]; |
Human Tissues Associated with Indication | Breast |
Reference | Chinese pharmacopoeia (2015) |
Reference Book/link | ISBN 978-7-5067-7337-9 |
Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
---|---|---|---|---|
TCMH228 | Bupleurum chinense | 柴胡 | TCMH228 | ITSAM2218-14 |
TCMH421 | Angelica sinensis | 当归 | TCMH421 | ITSAF173-14 |
TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
TCMH2532 | Curcuma aromatica | 郁金 | TCMH2532 | ITSAF2298-14 |
TCMH720 | Tulipa edulis | 光慈菇 | TCMH720 | GBVT2777-13, GBVP2304-14 |
TCMH1331 | Rhaponticum uniflorum | 漏芦 | TCMH1331 | ITSAJ4341-14 |
TCMH1226 | Laminaria japonica | 昆布 | TCMH1226 | AB022790 |
TCMH797 | Sargassum | 海藻 | TCMH797 | |
TCMH2507 | Epimedium brevicornum | 淫羊藿 | TCMH2507 | AY362429 |
TCMH1359 | Pyrola calliantha | 鹿衔草 | TCMH1359 | FJ378582 |
Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
---|---|---|---|---|
TCMT102 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | Hydrolase | P24666 |
TCMT103 | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | Hydrolase | P10586 |
TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
TCMT130 | ALOX5 | Arachidonate 5-lipoxygenase | Oxidoreductase | P09917 |
TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
TCMT150 | RORC | Nuclear receptor ROR-gamma | Nuclear receptor | P51449 |
TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
TCMT161 | HCAR2 | Hydroxycarboxylic acid receptor 2 | GPCR | Q8TDS4 |
TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
TCMT187 | AR | Androgen Receptor | Nuclear receptor | P10275 |
TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
TCMT193 | RELA | Nuclear factor NF-kappa-B p65 subunit | Transcription factor | Q04206 |
TCMT194 | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 | Kinase | O43318 |
TCMT195 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | Q02750 |
TCMT196 | MAP2K7 | Dual specificity mitogen-activated protein kinase kinase 7 | Kinase | O14733 |
TCMT206 | CYP2A6 | Cytochrome P450 2A6 | Oxidoreductase | P11509 |
TCMT208 | MAOA | Monoamine oxidase A | Oxidoreductase | P21397 |
TCMT212 | SRC | Tyrosine-protein kinase SRC | Kinase | P12931 |
TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
TCMT217 | CYP2C8 | Cytochrome P450 2C8 | Oxidoreductase | P10632 |
TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
TCMT230 | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | Oxidoreductase | P37058 |
TCMT239 | PIM1 | Serine/threonine-protein kinase PIM1 | Kinase | P11309 |
TCMT240 | AMY1A | Salivary alpha-amylase | Unclassified | P04745 |
TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
TCMT260 | FLT3 | Tyrosine-protein kinase receptor FLT3 | Kinase | P36888 |
TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
TCMT268 | CYP2A13 | Cytochrome P450 2A13 | Oxidoreductase | Q16696 |
TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
TCMT301 | PTGES | Prostaglandin E synthase | Isomerase | O14684 |
TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
TCMT322 | MMP13 | Matrix metalloproteinase 13 | Hydrolase | P45452 |
TCMT369 | IGF1R | Insulin-like growth factor I receptor | Kinase | P08069 |
TCMT370 | KDR | Vascular endothelial growth factor receptor 2 | Kinase | P35968 |
TCMT374 | AURKB | Serine/threonine-protein kinase Aurora-B | Kinase | Q96GD4 |
TCMT388 | AXL | Tyrosine-protein kinase receptor UFO | Kinase | P30530 |
TCMT401 | MET | Hepatocyte growth factor receptor | Kinase | P08581 |
TCMT422 | CAMK2B | CaM kinase II beta | Kinase | Q13554 |
TCMT445 | NEK2 | Serine/threonine-protein kinase NEK2 | Kinase | P51955 |
TCMT45 | APP | Beta amyloid A4 protein | Unclassified | P05067 |
TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
TCMT462 | NEK6 | Serine/threonine-protein kinase NEK6 | Kinase | Q9HC98 |
TCMT479 | AKT1 | Serine/threonine-protein kinase AKT | Kinase | P31749 |
TCMT484 | PLK1 | Serine/threonine-protein kinase PLK1 | Kinase | P53350 |
TCMT560 | F10 | Coagulation factor X | Unclassified | P00742 |
TCMT565 | EP300 | Histone acetyltransferase p300 | Transferase | Q09472 |
TCMT566 | NOS2 | Nitric oxide synthase, inducible | Oxidoreductase | P35228 |
TCMT570 | ANPEP | Aminopeptidase N | Unclassified | P15144 |
TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
TCMT598 | TOP1 | DNA topoisomerase I | Isomerase | P11387 |
TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
TCMT690 | HDAC3 | Histone deacetylase 3 | Hydrolase | O15379 |
TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
TCMT725 | CACNA1C | Voltage-gated L-type calcium channel alpha-1C subunit | Ion channel | Q13936 |
TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
TCMT784 | AVPR2 | Vasopressin V2 receptor | GPCR | P30518 |
TCMT785 | CXCR1 | Interleukin-8 receptor A | GPCR | P25024 |
TCMT786 | CCR4 | C-C chemokine receptor type 4 | GPCR | P51679 |
TCMT791 | PKN1 | Protein kinase N1 | Kinase | Q16512 |
TCMT793 | PYGL | Liver glycogen phosphorylase | Transferase | P06737 |
TCMT80 | MAPK1 | MAP kinase ERK2 | Kinase | P28482 |
TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
TCMT87 | CYP2C9 | Cytochrome P450 2C9 | Oxidoreductase | P11712 |
TCMT99 | SHBG | Testis-specific androgen-binding protein | Unclassified | P04278 |
Target ID | Target Name |
---|---|
TCMT1178 | Actinomyces viscosus |
TCMT1181 | Mycobacterium tuberculosis H37Ra |
TCMT1190 | Plasmodium falciparum (isolate FcB1 / Columbia) |
TCMT1208 | Escherichia coli K12 |
TCMT1209 | Staphylococcus haemolyticus |
TCMT1210 | Streptococcus sobrinus |
TCMT1211 | Fusobacterium nucleatum |
TCMT1212 | Verticillium dahliae |
TCMT1215 | Pseudomonas aeruginosa PAO1 |
TCMT1218 | Staphylococcus aureus |
TCMT1221 | Human herpesvirus 4 |
TCMT1222 | Plasmodium falciparum D6 |
TCMT1223 | Staphylococcus epidermidis |
TCMT1224 | Proteus mirabilis |
TCMT1226 | Klebsiella pneumoniae |
TCMT1227 | Streptococcus |
TCMT1229 | Enterococcus faecalis |
TCMT1232 | Pseudomonas aeruginosa |
TCMT1243 | Aspergillus flavus |
TCMT1245 | Phytophthora cactorum |
TCMT1246 | Escherichia coli |
TCMT1249 | Dengue virus 2 |
TCMT1251 | Candida albicans |
TCMT1253 | Penicillium chrysogenum |
TCMT1255 | Human immunodeficiency virus 1 |
TCMT1284 | Penicillium expansum |
TCMT1286 | Bacillus cereus |
TCMT1294 | Human parainfluenza virus 3 |
TCMT1313 | Human immunodeficiency virus 2 |
TCMT1314 | Streptococcus viridans |
TCMT1321 | Staphylococcus hominis |
TCMT1343 | Staphylococcus simulans |
TCMT1344 | Staphylococcus sciuri |
TCMT1346 | Helicobacter pylori |
TCMT1349 | Helicobacter pylori SS1 |
TCMT1361 | Neisseria meningitidis |
TCMT1370 | Prevotella melaninogenica |
TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
TCMT1384 | Fusarium tricinctum |
TCMT1408 | Colletotrichum gloeosporioides |
TCMT1412 | Salmonella typhimurium |
TCMT1438 | Plasmodium falciparum |
TCMT1439 | Mycobacterium smegmatis |
TCMT1442 | Leishmania donovani |
TCMT1443 | Leishmania amazonensis |
TCMT1444 | Fusarium oxysporum |
TCMT1447 | Respiratory syncytial virus |
TCMT1448 | Enterobacter aerogenes |
TCMT1449 | Influenza A virus |
TCMT1450 | Plasmodium falciparum 3D7 |
TCMT1454 | Bacillus subtilis |
TCMT1455 | Mycobacterium tuberculosis H37Rv |
TCMT1458 | Filobasidiella neoformans |
TCMT1462 | Streptococcus mutans |
TCMT1463 | Mycobacterium tuberculosis |
TCMT1464 | Hepatitis B virus |
TCMT1465 | Entamoeba histolytica |
GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
---|---|---|---|
[BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.6946 |
[BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.6988 |
[BP] GO:0044281 | small molecule metabolic process | AKR1B1, ALOX5, APP, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FUT7, HSD17B3, PIM1, PPARA, PTGES, XDH | 8.83506 |
[BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, ALOX5, APP, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FABP4, FUT7, HSD17B1, HSD17B3, MET, PPARA, PTGES | 7.17418 |
[BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, APP, AR, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 6.61208 |
[BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, APP, AR, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 6.60878 |
[BP] GO:0010035 | response to inorganic substance | AKR1B1, APP, AXL, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, KDR, MMP9, PTGES, RELA, SRC | 6.33061 |
[BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 6.23256 |
[BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 5.75886 |
[BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.47363 |
[BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 5.40125 |
[BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, APP, AR, AXL, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, IGF1R, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC | 5.27419 |
[BP] GO:1902533 | positive regulation of intracellular signal transduction | ADORA1, AKR1B1, APP, AR, AXL, CYP1B1, F10, F3, FLT3, KDR, MAP2K1, MAP3K7, MET, RELA, SRC, XDH | 5.27419 |
[BP] GO:0019748 | secondary metabolic process | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.27419 |
[BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, APP, AR, CSNK2A1, CYP1B1, F3, FABP3, FLT3, IGF1R, KDR, MAP2K1, MMP2, MMP9, PIM1, PTGES, RELA, SRC, XDH | 5.25678 |
[BP] GO:0010941 | regulation of cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PIM1, PPARA, RELA, SRC, XDH | 5.25112 |
[BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA12, CA2, CA7, CACNA1C, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FABP4, FLT3, HCAR2, HSD17B1, HSD17B3, KDR, MAOA, MET, PPARA, SRC, XDH | 5.20658 |
[BP] GO:0019369 | arachidonic acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 5.18734 |
[BP] GO:0033559 | unsaturated fatty acid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 5.14934 |
[BP] GO:0043067 | regulation of programmed cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PIM1, RELA, SRC, XDH | 5.04261 |
[BP] GO:0006690 | icosanoid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 4.9935 |
[BP] GO:0008202 | steroid metabolic process | AKR1B1, APP, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, HSD17B1, HSD17B3 | 4.78768 |
[BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 4.78633 |
[BP] GO:0010033 | response to organic substance | AKR1B1, APP, AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FLT3, IGF1R, KDR, MMP2, PPARA, PTGES, RELA, RORC, SRC | 4.69745 |
[BP] GO:1902531 | regulation of intracellular signal transduction | ADORA1, AKR1B1, APP, AR, AURKB, AXL, CSNK2A1, CYP1B1, F10, F3, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.6455 |
[BP] GO:0042221 | response to chemical | AKR1B1, APP, AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FLT3, IGF1R, KDR, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC, TOP1 | 4.49282 |
[BP] GO:0033993 | response to lipid | AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FABP3, FLT3, PTGES, RELA, RORC, SRC | 4.45403 |
[BP] GO:0042981 | regulation of apoptotic process | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MMP9, PIM1, RELA, SRC, XDH | 4.45403 |
[BP] GO:0014070 | response to organic cyclic compound | APP, AR, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, PTGES, RELA, RORC, SRC | 4.43488 |
[BP] GO:0009967 | positive regulation of signal transduction | ADORA1, AKR1B1, APP, AR, AXL, CSNK2A1, CYP1B1, F10, F3, FLT3, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.43488 |
[BP] GO:0048513 | animal organ development | ACHE, AR, AXL, CA2, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, HSD17B3, KDR, MAP2K1, PPARA, RELA, SRC | 4.36791 |
[BP] GO:0006631 | fatty acid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGES | 4.26437 |
[BP] GO:0010646 | regulation of cell communication | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.02693 |
[BP] GO:0060548 | negative regulation of cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MET, MMP9, PIM1, PPARA, RELA, SRC | 4.00356 |
[BP] GO:1901568 | fatty acid derivative metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 4.00356 |
[BP] GO:0044255 | cellular lipid metabolic process | ACHE, ALOX5, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FABP4, FUT7, MET, PPARA, PTGES | 3.96062 |
[BP] GO:0023051 | regulation of signaling | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 3.96062 |
[BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, XDH | 3.92738 |
[BP] GO:0001676 | long-chain fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 3.88201 |
[BP] GO:0009719 | response to endogenous stimulus | AKR1B1, APP, AR, CA2, CA9, CSNK2A1, CYP1A2, FABP3, FLT3, IGF1R, MMP2, PPARA, RELA, SRC | 3.88155 |
[BP] GO:0030522 | intracellular receptor signaling pathway | AR, MAP3K7, PIM1, PPARA, RELA, RORC, SRC | 3.71283 |
[BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, HSD17B1, HSD17B3 | 3.71283 |
[BP] GO:0034614 | cellular response to reactive oxygen species | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 3.71283 |
[BP] GO:0043069 | negative regulation of programmed cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MET, MMP9, PIM1, RELA, SRC | 3.69842 |
[BP] GO:0009698 | phenylpropanoid metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.6325 |
[BP] GO:0009804 | coumarin metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.6325 |
[BP] GO:0048584 | positive regulation of response to stimulus | ADORA1, AKR1B1, APP, AR, AXL, CSNK2A1, CYP1B1, F10, F3, FABP4, FLT3, KDR, MAP2K1, MAP3K7, MET, MMP2, MMP9, RELA, SRC, XDH | 3.63083 |
[BP] GO:0051270 | regulation of cellular component movement | ADORA1, ADORA3, APP, CACNA1C, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.61294 |
[BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, HSD17B1, HSD17B3 | 3.61294 |
[BP] GO:0032879 | regulation of localization | ACHE, ADORA1, ADORA3, APP, AR, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PPARA, SRC | 3.61294 |
[BP] GO:0018108 | peptidyl-tyrosine phosphorylation | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.61294 |
[BP] GO:0018212 | peptidyl-tyrosine modification | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.57211 |
[BP] GO:0030334 | regulation of cell migration | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.48939 |
[BP] GO:0046777 | protein autophosphorylation | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1, SRC | 3.48332 |
[BP] GO:0048518 | positive regulation of biological process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FABP4, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, XDH | 3.46854 |
[BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CACNA1C, CYP19A1, CYP1A1, CYP1B1, HCAR2, HSD17B1, HSD17B3 | 3.46854 |
[BP] GO:0009056 | catabolic process | ACHE, ADORA1, AURKB, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, FABP3, FABP4, FUT7, MAOA, MMP1, MMP2, MMP9, SRC, XDH | 3.4651 |
[BP] GO:0006468 | protein phosphorylation | APP, AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.45117 |
[BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, APP, AR, AURKB, AXL, CA2, CA6, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, F10, F3, FABP3, FABP4, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC, TOP1 | 3.36433 |
[BP] GO:0009725 | response to hormone | AKR1B1, AR, CA2, CA9, CSNK2A1, CYP1A2, FABP3, FLT3, PPARA, RELA, SRC | 3.35789 |
[BP] GO:0070887 | cellular response to chemical stimulus | AKR1B1, APP, AR, AXL, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, IGF1R, KDR, MMP2, MMP9, RELA, RORC, SRC | 3.33748 |
[BP] GO:2000145 | regulation of cell motility | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.25332 |
[BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.22329 |
[BP] GO:0043066 | negative regulation of apoptotic process | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MMP9, PIM1, RELA, SRC | 3.10196 |
[BP] GO:0051716 | cellular response to stimulus | AKR1B1, APP, AR, AURKB, AXL, CA2, CA9, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MMP2, MMP9, RELA, RORC, SRC | 3.08378 |
[BP] GO:0018193 | peptidyl-amino acid modification | AURKB, AXL, CSNK2A1, F10, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, SRC, TOP1 | 3.00243 |
[BP] GO:0071310 | cellular response to organic substance | AKR1B1, APP, AR, AXL, CYP1A1, CYP1B1, FABP4, FLT3, IGF1R, KDR, MMP2, RELA, RORC, SRC | 2.99575 |
[BP] GO:0040012 | regulation of locomotion | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.95072 |
[BP] GO:0055114 | oxidation-reduction process | AKR1B1, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, HSD17B3, MAOA, XDH | 2.93035 |
[BP] GO:0032501 | multicellular organismal process | ADORA1, AKR1B1, ALOX5, APP, AR, AXL, CACNA1C, CYP19A1, CYP1A2, CYP1B1, F10, F3, FABP4, IGF1R, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, TOP1 | 2.8956 |
[BP] GO:1901701 | cellular response to oxygen-containing compound | AKR1B1, APP, AR, AXL, CYP1B1, IGF1R, MMP2, MMP9, RELA, RORC, SRC | 2.87859 |
[BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, APP, AR, AXL, CA2, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, HSD17B3, KDR, MAP2K1, MMP9, PIM1, PPARA, RELA, RORC, SRC | 2.87859 |
[BP] GO:0032787 | None | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGES | 2.86669 |
[BP] GO:0019216 | regulation of lipid metabolic process | ADORA1, CYP1A1, FABP3, FLT3, HCAR2, PPARA, RORC, SRC | 2.83512 |
[BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, FUT7, HSD17B3, KDR, MAP2K1, MET, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC | 2.74884 |
[BP] GO:0000302 | response to reactive oxygen species | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 2.74871 |
[BP] GO:1901654 | None | AKR1B1, AR, CA9, CSNK2A1, RELA, SRC | 2.69634 |
[BP] GO:0043410 | positive regulation of MAPK cascade | ADORA1, APP, AR, FLT3, KDR, MAP2K1, MAP3K7, SRC, XDH | 2.66573 |
[BP] GO:0042542 | response to hydrogen peroxide | AKR1B1, AXL, CYP1B1, RELA, SRC | 2.60496 |
[BP] GO:0016310 | phosphorylation | APP, AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 2.59398 |
[BP] GO:0051240 | positive regulation of multicellular organismal process | APP, AR, AXL, CA2, CYP1B1, F3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, PIM1, RELA, SRC | 2.58368 |
[BP] GO:0034599 | cellular response to oxidative stress | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 2.51002 |
[BP] GO:0006805 | xenobiotic metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, RORC | 2.51002 |
[BP] GO:0097237 | cellular response to toxic substance | AKR1B1, AXL, CYP1B1, KDR, RELA | 2.40961 |
[BP] GO:0043393 | regulation of protein binding | APP, AURKB, MET, MMP9, PPARA, SRC | 2.38654 |
[BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.38363 |
[BP] GO:2000021 | regulation of ion homeostasis | ADORA1, CA2, CA7, CACNA1C, KDR, SRC | 2.36181 |
[BP] GO:0070301 | cellular response to hydrogen peroxide | AKR1B1, AXL, CYP1B1, RELA | 2.35247 |
[BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD17B1, HSD17B3 | 2.35247 |
[BP] GO:0043408 | regulation of MAPK cascade | ADORA1, APP, AR, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, SRC, XDH | 2.34331 |
[BP] GO:0051896 | regulation of protein kinase B signaling | AXL, F10, F3, MET, SRC, XDH | 2.34083 |
[BP] GO:0008284 | positive regulation of cell proliferation | AKR1B1, AR, CSNK2A1, F3, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, RELA | 2.31716 |
[BP] GO:0010038 | response to metal ion | APP, CA2, CYP1A1, CYP1A2, FABP4, MMP9, PTGES | 2.3136 |
[BP] GO:0030335 | positive regulation of cell migration | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.30757 |
[BP] GO:0001101 | response to acid chemical | AKR1B1, FABP3, KDR, MMP2, PTGES, RELA, SRC | 2.29439 |
[BP] GO:0042493 | response to drug | AKR1B1, AXL, CA9, CYP1A1, CYP1B1, FABP3, KDR, RELA, SRC, TOP1 | 2.27216 |
[BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.23661 |
[BP] GO:0080134 | regulation of response to stress | ADORA1, APP, CYP19A1, F3, FABP4, IGF1R, MAP2K1, MAP3K7, MET, MMP2, PPARA, RELA, SRC, XDH | 2.23279 |
[BP] GO:2000147 | positive regulation of cell motility | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.21441 |
[BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1 | 2.19245 |
[BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.19245 |
[BP] GO:0006979 | response to oxidative stress | AKR1B1, APP, AXL, CYP1B1, MMP9, RELA, SRC | 2.14981 |
[BP] GO:0051272 | positive regulation of cellular component movement | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.14981 |
[BP] GO:0032847 | regulation of cellular pH reduction | CA2, CA7 | 2.14981 |
[BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.14981 |
[BP] GO:0006811 | None | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, FABP3, PPARA | 2.13933 |
[BP] GO:0032844 | regulation of homeostatic process | ADORA1, AURKB, CA2, CA7, CACNA1C, HCAR2, KDR, SRC | 2.13083 |
[BP] GO:1901652 | response to peptide | AKR1B1, APP, FABP3, IGF1R, PPARA, RELA, SRC | 2.11688 |
[BP] GO:0071407 | cellular response to organic cyclic compound | APP, AR, CYP1A1, CYP1B1, FLT3, RORC, SRC | 2.10422 |
[BP] GO:0040017 | positive regulation of locomotion | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.05741 |
[BP] GO:0051897 | positive regulation of protein kinase B signaling | AXL, F10, F3, MET, SRC | 2.01329 |
[CC] GO:0005641 | nuclear envelope lumen | ALOX5, APP, PTGES | 3.48939 |
[CC] GO:0031233 | None | CA4, F10, F3 | 2.38396 |
[CC] GO:0016020 | membrane | ACHE, ADORA1, ADORA3, ALOX5, APP, AR, AXL, CA12, CA14, CA2, CA4, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FLT3, FUT7, HCAR2, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP2, PIM1, PTGES, SRC | 1.79026 |
[CC] GO:0005886 | plasma membrane | ACHE, ADORA1, ADORA3, APP, AR, AXL, CA12, CA14, CA2, CA4, CA9, CACNA1C, CSNK2A1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP2, PIM1, SRC | 1.77494 |
[CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, ALOX5, APP, AR, AURKB, CA1, CA2, CA4, CA5A, CA5B, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, KDR, MAOA, MAP2K1, MAP3K7, MMP2, MMP9, PIM1, PTGES, RELA, SRC, TOP1, XDH | 1.65784 |
[MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 18.1084 |
[MF] GO:0046914 | transition metal ion binding | ALOX5, APP, AR, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 12.93 |
[MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.758 |
[MF] GO:0043167 | ion binding | ACHE, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FABP3, FABP4, FLT3, HSD17B1, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 11.6554 |
[MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 10.5667 |
[MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, ALOX5, AURKB, AXL, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PTGES, SRC, TOP1, XDH | 9.37791 |
[MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.83747 |
[MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 6.83747 |
[MF] GO:0008270 | zinc ion binding | AR, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PPARA, RORC | 5.38534 |
[MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 5.32398 |
[MF] GO:0005506 | iron ion binding | ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, XDH | 5.01599 |
[MF] GO:0043169 | cation binding | ACHE, ALOX5, APP, AR, AURKB, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, MAP3K7, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 5.01599 |
[MF] GO:0046872 | metal ion binding | ALOX5, APP, AR, AURKB, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, MAP3K7, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 4.6455 |
[MF] GO:0020037 | heme binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, SRC | 4.45403 |
[MF] GO:0008144 | drug binding | ACHE, AURKB, AXL, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, PPARA, SRC, TOP1 | 4.34626 |
[MF] GO:0046906 | tetrapyrrole binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, SRC | 4.29626 |
[MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 4.15216 |
[MF] GO:0004672 | protein kinase activity | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 4.07933 |
[MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.98356 |
[MF] GO:0016491 | oxidoreductase activity | AKR1B1, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, HSD17B3, MAOA, XDH | 3.67694 |
[MF] GO:0004713 | protein tyrosine kinase activity | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.63621 |
[MF] GO:0048037 | cofactor binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, PTGES, SRC, XDH | 3.61294 |
[MF] GO:0004714 | transmembrane receptor protein tyrosine kinase activity | AXL, FLT3, IGF1R, KDR, MET | 3.61294 |
[MF] GO:0016773 | phosphotransferase activity, alcohol group as acceptor | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.45117 |
[MF] GO:0008395 | steroid hydroxylase activity | CYP19A1, CYP1A1, CYP2A13, CYP2A6 | 3.23052 |
[MF] GO:0019199 | transmembrane receptor protein kinase activity | AXL, FLT3, IGF1R, KDR, MET | 3.18151 |
[MF] GO:0016301 | kinase activity | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.09628 |
[MF] GO:0042562 | hormone binding | ACHE, AR, HSD17B1, IGF1R, SHBG | 3.04292 |
[MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.99046 |
[MF] GO:0043168 | anion binding | APP, AURKB, AXL, CSNK2A1, F10, F3, FABP3, FABP4, FLT3, HSD17B1, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, PTGES, RELA, SRC, TOP1, XDH | 2.88224 |
[MF] GO:0008389 | None | CYP2A13, CYP2A6 | 2.80249 |
[MF] GO:0008289 | lipid binding | AR, AXL, F10, F3, FABP3, FABP4, HSD17B1, PPARA, RORC, SHBG | 2.52785 |
[MF] GO:0016772 | transferase activity, transferring phosphorus-containing groups | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 2.47071 |
[MF] GO:0005497 | None | AR, SHBG | 2.14981 |
KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
---|---|---|
Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 19.5677 |
Ovarian steroidogenesis_Homo sapiens_hsa04913 | ALOX5, HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R | 6.4556 |
Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD17B1, CYP1A2, CYP1A1, HSD17B3, CYP1B1, CYP19A1 | 6.2328 |
Bladder cancer_Homo sapiens_hsa05219 | MAP2K1, SRC, MMP1, MMP2, MMP9 | 5.465 |
Pathways in cancer_Homo sapiens_hsa05200 | AR, MAP2K1, FLT3, MMP1, MMP2, MMP9, MET, RELA, IGF1R | 4.5519 |
Proteoglycans in cancer_Homo sapiens_hsa05205 | MAP2K1, SRC, MMP2, KDR, MMP9, MET, IGF1R | 4.5519 |
Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 4.514 |
Adherens junction_Homo sapiens_hsa04520 | CSNK2A1, SRC, MAP3K7, MET, IGF1R | 4.514 |
Chemical carcinogenesis_Homo sapiens_hsa05204 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 4.338 |
cAMP signaling pathway_Homo sapiens_hsa04024 | HCAR2, MAP2K1, ADORA1, CACNA1C, PPARA, RELA | 3.7003 |
Tryptophan metabolism_Homo sapiens_hsa00380 | MAOA, CYP1A2, CYP1A1, CYP1B1 | 4.2154 |
Serotonergic synapse_Homo sapiens_hsa04726 | APP, MAP2K1, MAOA, ALOX5, CACNA1C | 3.752 |
Acute myeloid leukemia_Homo sapiens_hsa05221 | MAP2K1, FLT3, PIM1, RELA | 3.6992 |
Metabolic pathways_Homo sapiens_hsa01100 | CYP2A6, FUT7, MAOA, ALOX5, HSD17B1, CYP1A2, CYP1A1, HSD17B3, AKR1B1, CYP19A1, XDH, PTGES | 3.0221 |
Prostate cancer_Homo sapiens_hsa05215 | AR, MAP2K1, RELA, IGF1R | 3.0202 |
GnRH signaling pathway_Homo sapiens_hsa04912 | MAP2K1, SRC, MMP2, CACNA1C | 3.0075 |
AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, PIM1, F3, RELA | 2.8989 |
PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.3995 |
Estrogen signaling pathway_Homo sapiens_hsa04915 | MAP2K1, SRC, MMP2, MMP9 | 2.9115 |
Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | FLT3, MMP9, MET, RELA, IGF1R | 2.9666 |
Focal adhesion_Homo sapiens_hsa04510 | MAP2K1, SRC, KDR, MET, IGF1R | 2.7967 |
Rap1 signaling pathway_Homo sapiens_hsa04015 | MAP2K1, SRC, KDR, MET, IGF1R | 2.7469 |
TNF signaling pathway_Homo sapiens_hsa04668 | MAP2K1, MMP9, MAP3K7, RELA | 2.7959 |
Ras signaling pathway_Homo sapiens_hsa04014 | MAP2K1, KDR, MET, RELA, IGF1R | 2.6356 |
Sphingolipid signaling pathway_Homo sapiens_hsa04071 | MAP2K1, ADORA3, ADORA1, RELA | 2.6876 |
Hepatitis B_Homo sapiens_hsa05161 | MAP2K1, SRC, MMP9, RELA | 2.4147 |
Caffeine metabolism_Homo sapiens_hsa00232 | CYP2A6, CYP1A2, XDH | 5.2108 |
VEGF signaling pathway_Homo sapiens_hsa04370 | MAP2K1, SRC, KDR | 2.4336 |
cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | MAP2K1, ADORA3, ADORA1, CACNA1C | 2.294 |
MicroRNAs in cancer_Homo sapiens_hsa05206 | MAP2K1, PIM1, CYP1B1, MMP9, MET | 2.2506 |
PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | MAP2K1, KDR, MET, RELA, IGF1R | 2.0222 |
Central carbon metabolism in cancer_Homo sapiens_hsa05230 | MAP2K1, FLT3, MET | 2.36 |
Melanoma_Homo sapiens_hsa05218 | MAP2K1, MET, IGF1R | 2.3281 |
Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | SRC, MET, RELA | 2.3556 |
Prolactin signaling pathway_Homo sapiens_hsa04917 | MAP2K1, SRC, RELA | 2.3234 |
Retinol metabolism_Homo sapiens_hsa00830 | CYP2A6, CYP1A2, CYP1A1 | 2.3837 |
Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP2A6, MAOA, CYP1A2 | 2.3509 |
Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, MAP2K1, CACNA1C | 1.8871 |
HIF-1 signaling pathway_Homo sapiens_hsa04066 | MAP2K1, RELA, IGF1R | 1.9473 |
Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | MAP2K1, MAP3K7, RELA | 1.9333 |
T cell receptor signaling pathway_Homo sapiens_hsa04660 | MAP2K1, MAP3K7, RELA | 1.9462 |
MAPK signaling pathway_Homo sapiens_hsa04010 | MAP2K1, CACNA1C, MAP3K7, RELA | 1.7476 |
NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, MAP3K7, RELA | 2.0514 |
Endocytosis_Homo sapiens_hsa04144 | SRC, KDR, MET, IGF1R | 1.7333 |
Toxoplasmosis_Homo sapiens_hsa05145 | ALOX5, MAP3K7, RELA | 1.8225 |
Oocyte meiosis_Homo sapiens_hsa04114 | AR, MAP2K1, IGF1R | 1.7817 |
Osteoclast differentiation_Homo sapiens_hsa04380 | MAP2K1, MAP3K7, RELA | 1.7245 |
Measles_Homo sapiens_hsa05162 | CSNK2A1, MAP3K7, RELA | 1.6975 |
Oxytocin signaling pathway_Homo sapiens_hsa04921 | MAP2K1, SRC, CACNA1C | 1.5447 |
Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1, MAP3K7, RELA | 1.4489 |
Chemokine signaling pathway_Homo sapiens_hsa04062 | MAP2K1, SRC, RELA | 1.4489 |
Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, MAP3K7, RELA | 1.4001 |
Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | FLT3, KDR, MET | 1.1438 |
Glioma_Homo sapiens_hsa05214 | MAP2K1, IGF1R | 1.4489 |
Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.5025 |
Long-term depression_Homo sapiens_hsa04730 | MAP2K1, IGF1R | 1.4612 |
Renin secretion_Homo sapiens_hsa04924 | ADORA1, CACNA1C | 1.4489 |
Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | MAP2K1, IGF1R | 1.2176 |
Insulin resistance_Homo sapiens_hsa04931 | PPARA, RELA | 1.1438 |
Neurotrophin signaling pathway_Homo sapiens_hsa04722 | MAP2K1, RELA | 1.0889 |
Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | MAP2K1, SRC | 1.0918 |
Apoptosis_Homo sapiens_hsa04210 | MAP2K1, RELA | 1.0036 |
ErbB signaling pathway_Homo sapiens_hsa04012 | MAP2K1, SRC | 1.2931 |
Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.0918 |
Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | RELA, IGF1R | 1.2455 |
Long-term potentiation_Homo sapiens_hsa04720 | MAP2K1, CACNA1C | 1.4489 |
AMPK signaling pathway_Homo sapiens_hsa04152 | MAP3K7, IGF1R | 1.0684 |
B cell receptor signaling pathway_Homo sapiens_hsa04662 | MAP2K1, RELA | 1.4101 |
Pancreatic cancer_Homo sapiens_hsa05212 | MAP2K1, RELA | 1.4489 |
Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | RORC, RELA | 1.4489 |
FoxO signaling pathway_Homo sapiens_hsa04068 | MAP2K1, IGF1R | 1.0336 |
Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA, RELA | 0.9638 |
Vascular smooth muscle contraction_Homo sapiens_hsa04270 | MAP2K1, CACNA1C | 1.0889 |
Tight junction_Homo sapiens_hsa04530 | CSNK2A1, SRC | 1.0044 |
Dopaminergic synapse_Homo sapiens_hsa04728 | MAOA, CACNA1C | 1.0475 |
Chronic myeloid leukemia_Homo sapiens_hsa05220 | MAP2K1, RELA | 1.4101 |
Hepatitis C_Homo sapiens_hsa05160 | PPARA, RELA | 1.0336 |
Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | MAP2K1, IGF1R | 1.002 |
NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | MAP3K7, RELA | 1.4958 |
Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1, MAP3K7 | 1.002 |
Arachidonic acid metabolism_Homo sapiens_hsa00590 | ALOX5, PTGES | 1.4489 |
Renal cell carcinoma_Homo sapiens_hsa05211 | MAP2K1, MET | 1.4489 |
HTLV-I infection_Homo sapiens_hsa05166 | RELA | 0.2972 |
GABAergic synapse_Homo sapiens_hsa04727 | SRC, CACNA1C | 1.2931 |
Amphetamine addiction_Homo sapiens_hsa05031 | MAOA, CACNA1C | 1.4489 |
Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA, RELA | 1.4257 |
Shigellosis_Homo sapiens_hsa05131 | SRC, RELA | 1.4489 |
Gap junction_Homo sapiens_hsa04540 | MAP2K1, SRC | 1.2931 |
Alzheimer's disease_Homo sapiens_hsa05010 | APP, CACNA1C | 0.9101 |
Leishmaniasis_Homo sapiens_hsa05140 | MAP3K7, RELA | 1.4101 |
Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | SRC, MET | 1.3679 |
Influenza A_Homo sapiens_hsa05164 | MAP2K1, RELA | 0.8962 |
Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | MAP2K1, SRC | 0.7849 |
Alcoholism_Homo sapiens_hsa05034 | MAP2K1, MAOA | 0.8918 |
Tuberculosis_Homo sapiens_hsa05152 | SRC, RELA | 0.8918 |
Viral carcinogenesis_Homo sapiens_hsa05203 | SRC, RELA | 0.8119 |
Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.415 |
Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.6486 |
Calcium signaling pathway_Homo sapiens_hsa04020 | CACNA1C | 0.4101 |
Cocaine addiction_Homo sapiens_hsa05030 | MAOA, RELA | 1.5977 |
Complement and coagulation cascades_Homo sapiens_hsa04610 | F10, F3 | 1.3634 |
RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | MAP3K7, RELA | 1.4257 |
Jak-STAT signaling pathway_Homo sapiens_hsa04630 | PIM1 | 0.4495 |
Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | CACNA1C | 0.4699 |
Phospholipase D signaling pathway_Homo sapiens_hsa04072 | MAP2K1 | 0.4769 |
Insulin signaling pathway_Homo sapiens_hsa04910 | MAP2K1 | 0.4869 |
Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | MAP2K1 | 0.4946 |
Axon guidance_Homo sapiens_hsa04360 | MET | 0.5141 |
Platelet activation_Homo sapiens_hsa04611 | SRC | 0.5261 |
Glutamatergic synapse_Homo sapiens_hsa04724 | CACNA1C | 0.5484 |
Drug metabolism - other enzymes_Homo sapiens_hsa00983 | CYP2A6, XDH | 1.6423 |
Melanogenesis_Homo sapiens_hsa04916 | MAP2K1 | 0.5882 |
Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | RELA | 0.5799 |
Amoebiasis_Homo sapiens_hsa05146 | RELA | 0.5882 |
Choline metabolism in cancer_Homo sapiens_hsa05231 | MAP2K1 | 0.5882 |
Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | MAP2K1 | 0.5935 |
Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5882 |
Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | SRC | 0.5882 |
Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5913 |
Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5902 |
Circadian entrainment_Homo sapiens_hsa04713 | CACNA1C | 0.5913 |
Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5988 |
Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.6 |
Hematopoietic cell lineage_Homo sapiens_hsa04640 | FLT3 | 0.6 |
Taste transduction_Homo sapiens_hsa04742 | CACNA1C | 0.6094 |
Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | CACNA1C | 0.5882 |
Dilated cardiomyopathy_Homo sapiens_hsa05414 | CACNA1C | 0.6 |
Insulin secretion_Homo sapiens_hsa04911 | CACNA1C | 0.6052 |
Salmonella infection_Homo sapiens_hsa05132 | RELA | 0.6052 |
Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6 |
Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | CACNA1C | 0.6094 |
Small cell lung cancer_Homo sapiens_hsa05222 | RELA | 0.6052 |
Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6094 |
Hypertrophic cardiomyopathy (HCM)_Homo sapiens_hsa05410 | CACNA1C | 0.6094 |
Cardiac muscle contraction_Homo sapiens_hsa04260 | CACNA1C | 0.6207 |
Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6347 |
Pertussis_Homo sapiens_hsa05133 | RELA | 0.6326 |
Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | MAP2K1 | 0.6544 |
Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6442 |
Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 | CACNA1C | 0.6347 |
Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | IGF1R | 0.6751 |
Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | RELA | 0.6751 |
Colorectal cancer_Homo sapiens_hsa05210 | MAP2K1 | 0.6807 |
Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B1 | 0.697 |
Non-small cell lung cancer_Homo sapiens_hsa05223 | MAP2K1 | 0.7144 |
Legionellosis_Homo sapiens_hsa05134 | RELA | 0.7181 |
Endometrial cancer_Homo sapiens_hsa05213 | MAP2K1 | 0.7371 |
Malaria_Homo sapiens_hsa05144 | MET | 0.754 |
Arginine and proline metabolism_Homo sapiens_hsa00330 | MAOA | 0.7493 |
Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.1061 |
Type II diabetes mellitus_Homo sapiens_hsa04930 | CACNA1C | 0.7585 |
Prion diseases_Homo sapiens_hsa05020 | MAP2K1 | 0.8693 |
Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | MAOA | 0.8219 |
Thyroid cancer_Homo sapiens_hsa05216 | MAP2K1 | 0.9101 |
Galactose metabolism_Homo sapiens_hsa00052 | AKR1B1 | 0.9052 |
Dorso-ventral axis formation_Homo sapiens_hsa04320 | MAP2K1 | 0.9278 |
Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8962 |
Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.9101 |
Tyrosine metabolism_Homo sapiens_hsa00350 | MAOA | 0.8693 |
Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B1 | 0.8918 |
Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B1 | 0.8614 |
Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.9348 |
Circadian rhythm_Homo sapiens_hsa04710 | RORC | 0.9052 |
Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.9278 |
Histidine metabolism_Homo sapiens_hsa00340 | MAOA | 0.9638 |
Phenylalanine metabolism_Homo sapiens_hsa00360 | MAOA | 1.0668 |